ES2116594T3 - Ansamicinas biciclicas y su uso como agentes antitumorales. - Google Patents

Ansamicinas biciclicas y su uso como agentes antitumorales.

Info

Publication number
ES2116594T3
ES2116594T3 ES94913896T ES94913896T ES2116594T3 ES 2116594 T3 ES2116594 T3 ES 2116594T3 ES 94913896 T ES94913896 T ES 94913896T ES 94913896 T ES94913896 T ES 94913896T ES 2116594 T3 ES2116594 T3 ES 2116594T3
Authority
ES
Spain
Prior art keywords
ansamicins
bicyclic
antitumoral agents
agents
antitumoral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94913896T
Other languages
English (en)
Inventor
Rodney C Schnur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2116594T3 publication Critical patent/ES2116594T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

ESTA INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA (I) EN DONDE R{SUP, 1}, R{SUP, 2}, R{SUP, 3} Y X SON SEGUN SE DEFINE EN LA DESCRIPCION. TALES COMPUESTOS SON UTILES COMO INHIBIDORES DE LOS ONCOGENES Y COMO AGENTES ANTITUMORALES.
ES94913896T 1993-04-07 1994-03-14 Ansamicinas biciclicas y su uso como agentes antitumorales. Expired - Lifetime ES2116594T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/044,521 US5387584A (en) 1993-04-07 1993-04-07 Bicyclic ansamycins

Publications (1)

Publication Number Publication Date
ES2116594T3 true ES2116594T3 (es) 1998-07-16

Family

ID=21932854

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94913896T Expired - Lifetime ES2116594T3 (es) 1993-04-07 1994-03-14 Ansamicinas biciclicas y su uso como agentes antitumorales.

Country Status (10)

Country Link
US (1) US5387584A (es)
EP (1) EP0693073B1 (es)
JP (1) JP2722280B2 (es)
AT (1) ATE166877T1 (es)
CA (1) CA2160137C (es)
DE (1) DE69410790T2 (es)
DK (1) DK0693073T3 (es)
ES (1) ES2116594T3 (es)
FI (1) FI106028B (es)
WO (1) WO1994022867A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852496B1 (en) 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
AU764603B2 (en) 1998-07-17 2003-08-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Water-soluble drugs and methods for their production
US6747055B1 (en) 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
WO2000033858A1 (en) * 1998-12-07 2000-06-15 Ecosmart Technologies, Inc. Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
ATE526019T1 (de) * 2000-07-28 2011-10-15 Sloan Kettering Inst Cancer Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
KR100850727B1 (ko) * 2000-11-02 2008-08-06 슬로안-케테링인스티튜트퍼캔서리서치 에이치에스피90에 결합하기 위한 소분자 조성물
AU2877202A (en) 2000-11-02 2002-05-15 Sloan Kettering Inst Cancer Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
AU2002252179A1 (en) * 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
JP2004529188A (ja) * 2001-05-23 2004-09-24 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 上昇に関連した癌の治療法
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
JP2005504086A (ja) * 2001-09-24 2005-02-10 コンフォーマ セラピューティクス コーポレーション １７−アリルアミノゲルダナマイシン（１７−ａａｇ）および他のアンサマイシン類を製造する方法
EP1923061A1 (en) 2001-09-24 2008-05-21 Conforma Therapeutic Corporation Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
AU2003217393B8 (en) * 2002-02-08 2009-06-25 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
CA2481683A1 (en) * 2002-04-10 2003-10-23 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
WO2005009345A2 (en) * 2003-06-13 2005-02-03 Kosan Biosciences, Inc. 2-desmethyl ansamycin compounds
CN100404029C (zh) * 2003-09-25 2008-07-23 中国医学科学院医药生物技术研究所 格尔德霉素（c-3559）在制备疱疹病毒生殖道感染药物中的应用
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
WO2005056531A1 (en) 2003-11-12 2005-06-23 Kosan Biosciences, Inc. 11-o-methylgeldanamycin compounds
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
ES2409351T3 (es) * 2003-12-23 2013-06-26 Infinity Discovery, Inc. Análogos de ansamicinas que contienen benzoquinona para el tratamiento de cáncer
WO2005072766A2 (en) * 2004-01-27 2005-08-11 Boys Town National Research Hospital Peptides that bind to hsp90 proteins
US20080171687A1 (en) * 2004-09-16 2008-07-17 Abraxis Bioscience, Inc. Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
CA2602257A1 (en) * 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
AU2006235105A1 (en) * 2005-04-07 2006-10-19 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same
CN101175489A (zh) * 2005-04-29 2008-05-07 高山生物科学股份有限公司 用17-aag或17-ag或其前药治疗多发性骨髓瘤的方法
KR20080007642A (ko) * 2005-04-29 2008-01-22 코산 바이오사이언시즈, 인코포레이티드 프로테아좀 억제제와 함께 17-ａａｇ 또는 17-ａｇ 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법
US20080032719A1 (en) * 2005-10-01 2008-02-07 Outland Research, Llc Centralized establishment-based tracking and messaging service
JP2008543941A (ja) * 2005-06-21 2008-12-04 インフィニティ・ディスカバリー・インコーポレイテッド アンサマイシン製剤およびその使用方法
US20070105874A1 (en) * 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
WO2007064926A2 (en) * 2005-12-01 2007-06-07 Conforma Therapeutics Corporation Compositions containing ansamycin
EP2617428A1 (en) 2006-08-15 2013-07-24 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP2121957A4 (en) * 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
JP5454943B2 (ja) * 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク． 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
BRPI0810835A2 (pt) * 2007-04-12 2015-06-16 Infinity Discovery Inc Formulações de hidroquinona ansamicina
EP2200653A2 (en) 2007-09-10 2010-06-30 University of Massachusetts Mitochondria-targeted anti-tumour agents
WO2009086170A1 (en) * 2007-12-21 2009-07-09 Joyant Pharmaceuticals, Inc. Diazonamide analogs with improved solubility
PL2254586T3 (pl) 2008-02-22 2015-09-30 Agency For Science Tech And Research Astarstar Cząstki mezenchymalnych komórek macierzystych
JP2011514169A (ja) 2008-03-17 2011-05-06 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 幹細胞培養のためのマイクロキャリア
JP5123429B2 (ja) * 2008-04-29 2013-01-23 ジョイアント ファーマスーティカルズ、インク． インドリン抗癌剤
US8153619B2 (en) * 2008-05-22 2012-04-10 Joyant Pharmaceuticals, Inc. Diazonamide analogs
EP2348845A4 (en) 2008-10-15 2013-01-23 Infinity Pharmaceuticals Inc ANSAMYCIN HYDROQUINONE COMPOSITIONS
EP2471918A4 (en) 2009-09-29 2013-06-05 Takeda Pharmaceutical SCREENING PROCESS
WO2011059763A2 (en) 2009-10-28 2011-05-19 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
WO2011053257A2 (en) 2009-11-02 2011-05-05 Agency For Science, Technology And Research (A*Star) Methods of monitoring cellular states
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
ES2652444T3 (es) 2011-04-22 2018-02-02 Joyant Pharmaceuticals, Inc. Análogos de diazonamida
EP3795694A3 (en) 2012-10-02 2021-06-23 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
KR20160104612A (ko) 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조성물
WO2015140005A1 (en) 2014-03-19 2015-09-24 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Method of generation of pluripotent cells
CN110087658A (zh) 2016-10-12 2019-08-02 新加坡科技研究局 一种用于冻干外泌体的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987035A (en) * 1974-04-05 1976-10-19 University Of Illinois Foundation Biologically active compounds
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug

Also Published As

Publication number Publication date
DE69410790T2 (de) 1998-10-01
EP0693073A1 (en) 1996-01-24
CA2160137C (en) 1999-02-09
ATE166877T1 (de) 1998-06-15
CA2160137A1 (en) 1994-10-13
JP2722280B2 (ja) 1998-03-04
DK0693073T3 (da) 1998-10-12
FI941580A (fi) 1994-10-08
FI941580A0 (fi) 1994-04-06
EP0693073B1 (en) 1998-06-03
DE69410790D1 (de) 1998-07-09
US5387584A (en) 1995-02-07
JPH08503960A (ja) 1996-04-30
FI106028B (fi) 2000-11-15
WO1994022867A1 (en) 1994-10-13

Similar Documents

Publication Publication Date Title
ES2116594T3 (es) Ansamicinas biciclicas y su uso como agentes antitumorales.
NO20001940D0 (no) Bicykliske kinase-inhibitorer
DE69825048D1 (de) Analoga von duocarmycin and cc-1065
PT970095E (pt) Novos inibidores benzimidazole de frutose-1,6-bisfosfatase
ES2146774T3 (es) Polimeros de ioneno que contienen aniones biologicamente activos.
LV12358A (lv) 7-(Aizvietoti)-9-(aizvietoti glicil)-amido-6-demetil-6-deoksitetraciklini
ES2138622T3 (es) Derivados de mercaptoacetilamido piridazo(1,2-a)(1,2)diazepina utilizados como inhibidores de encefalinasa y eca.
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
ATE271058T1 (de) Mycophenol bisphosponatverbindungen
ATE217629T1 (de) Phosphonooxymethyl oder methylthiomethylether von taxanderivaten als antitumormittel
MX9302906A (es) Derivados de mercaptoacetilamida novedosos utiles como inhibidores de la encefalinasa.
DK0873340T3 (da) Heterocyklisk substituerede cyclopentanforbindelser
DK0705100T3 (da) Terapeutiske substituerede guanidiner
MY111201A (en) New imidazopyridines
BG99177A (en) New 7 -substituted-4-aza-5 - cholestanones as inhibitors of 5 - reductase
MX9205678A (es) Heteroarilaminas como nuevos inhibidores de la acetilcolinesterasa.
MX9305092A (es) Nuevas 4, 5-dihidro-4-oxo-pirrolo(1, 2-alquinoxalinas y sus correspondientes aza-analogos y procedimiento para su elaboracion.
ES2139669T3 (es) Nuevos derivados triciclicos de indan-2-mercaptoacetilamida 2-substituidos utiles como inhibidores de la encefalinasa.
GR3029454T3 (en) Novel 9-n-bicyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines
ES2179864T3 (es) 4-benzoil-isoxazoles y su uso como herbicidas.
NO20002191L (no) Dofetilid polymorfer
DE69418050T2 (de) Antivirale analoge von difluorostaton
DK1017377T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande
GR1001385B (el) Παράγωγα ιμιδαζο 1,2-α (πυρρολο,?ειενο η φουρανο) 3,2-d αζεπίνης συν?έσεις και μέ?οδοι χρήσεως.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 693073

Country of ref document: ES